Latest Articles

Publication Date
Assessing the female urogenital-rectal axis microbiome: focus on endometriosis and recurrent implantation failure.

Emerging evidence suggests microbial dysbiosis may contribute to gynaecological pathologies, including endometriosis and recurrent implantation failure (RIF). The vaginal microbiome is well-characterised, with Lactobacillus-dominance as a hallmark of health, yet …

Published: July 21, 2026, midnight
Integrative Transcriptomic Analysis Identifies a Key Candidate Gene Bridging Inflammation and DNA Repair in Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory disorder characterized by the ectopic implantation of endometrial-like tissue. Although retrograde menstruation is highly prevalent, only a subset of women develops the disease. This …

Published: July 21, 2026, midnight
Associations between granulysin and ovarian endometriosis: A 2-sample Mendelian randomization study.

Endometriosis (EMS) is a chronic inflammatory disease defined by the presence of endometrial-like tissue outside the uterine cavity. Ovarian EMS is considered the most prevalent disease phenotype. However, the causal …

Published: July 19, 2026, midnight
Merck's Keytruda Meets Primary Endpoint in Phase 3 Frontline Endometrial Cancer Trial - BioPharm International

Merck's Keytruda Meets Primary Endpoint in Phase 3 Frontline Endometrial Cancer Trial BioPharm International

Published: July 16, 2026, 9:06 p.m.
Endometrial Ablation Devices Market size to Reach USD 1.62 - openPR.com

Endometrial Ablation Devices Market size to Reach USD 1.62 openPR.com

Published: July 16, 2026, 5:35 p.m.
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer - Oncodaily

Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer Oncodaily

Published: July 16, 2026, 4:40 p.m.
Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer - CancerNetwork

Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer CancerNetwork

Published: July 16, 2026, 3:40 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Sahm

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm

Published: July 16, 2026, 10:27 a.m.
Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper - Seoul Economic Daily

Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper Seoul Economic Daily

Published: July 16, 2026, 5:33 a.m.
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk

Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk

Published: July 15, 2026, 11:49 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!